Full Press Release Details
IDEAYA Announces First Patient In for Company Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in Neo Adjuvant Uveal Melanoma.
IDYA
IDEAYA Announces First Patient In for Company Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in Neo Adjuvant Uveal Melanoma
Key Takeaway: IDEAYA Announces First Patient In for Company Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in Neo Adjuvant Uveal Melanoma
Price reaction · baseline $25.62 (2023-08-15 close) · hit after-hours · 2 other IDYA headline(s) in the window, move may be shared
day 0 close · peak
-1.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma